# Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

> **NCT02211833** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 41 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BI 2536
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02211833
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211833, "Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02211833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*